Business Context and Reporting Period
Arcutis Biotherapeutics, Inc. filed this Form 8-K on September 3, 2021, reporting events occurring on September 2, 2021. The filing concerns changes to the company’s board of directors and related director compensation. It does not present quarterly or annual financial statements.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes Versus the Prior Comparable Period
- Keith R. Leonard Jr. was appointed as a Class I director for a term expiring at the 2024 Annual Meeting of Stockholders.
- Mr. Leonard was appointed to the Board’s Compensation Committee.
- Ricky Sun, Ph.D. resigned from the Board effective September 2, 2021. The filing states that the resignation was not due to any disagreement with the company or its operations, policies, or practices.
Guidance, Outlook, Risks, and Unusual Items
- Mr. Leonard received a stock option exercisable for 32,907 shares of common stock, vesting in three equal annual installments subject to continued service.
- He is eligible for an annual cash retainer of $40,000 for Board service and $7,500 for Compensation Committee service.
- The company will enter into its standard indemnification agreement with Mr. Leonard.
- The filing reports no appointment-related arrangements with other persons, family relationships with directors or executive officers, or related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Important Facts for Investors to Verify
- Confirm the effective dates and terms of Mr. Leonard’s appointment and Mr. Sun’s resignation.
- Review the company’s non-employee director compensation program and the detailed terms of the 32,907-share stock option.
- Assess the potential dilution and expense associated with the director option award.
- Review subsequent filings for additional board changes, committee assignments, or compensation adjustments.